These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31196736)

  • 1. Comprehensive review of the research employing the schizophrenia cognition rating scale (SCoRS).
    Harvey PD; Khan A; Atkins A; Walker TM; Keefe RSE
    Schizophr Res; 2019 Aug; 210():30-38. PubMed ID: 31196736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the Persian version of the Schizophrenia Cognition Rating Scale (SCoRS) in patients with schizophrenia.
    Mazhari S; Ghafaree-Nejad AR; Soleymani-Zade S; Keefe RSE
    Asian J Psychiatr; 2017 Jun; 27():12-15. PubMed ID: 28558882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interview-based assessment of cognition in schizophrenia: applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care.
    Vita A; Deste G; Barlati S; De Peri L; Giambra A; Poli R; Keefe RS; Sacchetti E
    Schizophr Res; 2013 May; 146(1-3):217-23. PubMed ID: 23510596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity.
    Keefe RS; Poe M; Walker TM; Kang JW; Harvey PD
    Am J Psychiatry; 2006 Mar; 163(3):426-32. PubMed ID: 16513863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale.
    Keefe RS; Davis VG; Spagnola NB; Hilt D; Dgetluck N; Ruse S; Patterson TD; Narasimhan M; Harvey PD
    Eur Neuropsychopharmacol; 2015 Feb; 25(2):176-84. PubMed ID: 25028065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognition.
    Ventura J; Reise SP; Keefe RS; Baade LE; Gold JM; Green MF; Kern RS; Mesholam-Gately R; Nuechterlein KH; Seidman LJ; Bilder RM
    Schizophr Res; 2010 Aug; 121(1-3):24-31. PubMed ID: 20542412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between daily living skills, cognition, and real-world functioning across stages of schizophrenia; a study with the Schizophrenia Cognition Rating Scale Japanese version.
    Higuchi Y; Sumiyoshi T; Seo T; Suga M; Takahashi T; Nishiyama S; Komori Y; Kasai K; Suzuki M
    Schizophr Res Cogn; 2017 Mar; 7():13-18. PubMed ID: 28740824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.
    Harvey PD; Ogasa M; Cucchiaro J; Loebel A; Keefe RS
    Schizophr Res; 2011 Apr; 127(1-3):188-94. PubMed ID: 21277745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Schizophrenia Cognition Rating Scale: validation of an interview-based assessment of cognitive functioning in Asian patients with schizophrenia.
    Chia MY; Chan WY; Chua KY; Lee H; Lee J; Lee R; Lim C; Tay E; Woon PS; Keefe RS; Sim K
    Psychiatry Res; 2010 Jun; 178(1):33-8. PubMed ID: 20451258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Schizophrenia Cognition Rating Scale Japanese version (SCoRS-J) as a co-primary measure assessing cognitive function in schizophrenia].
    Kaneda Y; Ueoka Y; Sumiyoshi T; Yasui-Furukori N; Ito T; Higuchi Y; Suzuki M; Ohmori T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Nov; 31(5-6):259-62. PubMed ID: 22256616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interview-based assessment of cognition is a strong predictor of quality of life in patients with schizophrenia and severe negative symptoms.
    Cruz BF; Resende CB; Carvalhaes CF; Cardoso CS; Teixeira AL; Keefe RS; Rocha FL; Salgado JV
    Braz J Psychiatry; 2016; 38(3):216-21. PubMed ID: 27304257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the Chinese Version of the Schizophrenia Cognition Rating Scale.
    Huang KW; Lin PY; Lee Y; Huang YC; Hung CF; Lee SY; Chen CK; Wang LJ
    Psychiatry Investig; 2022 Jul; 19(7):511-518. PubMed ID: 35903053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between Performance-Based and Interview-Based Cognitive Measurements in Patients with Schizophrenia.
    Jeon DW; Jung DU; Oh M; Moon JJ; Kim SJ; Kim YS
    Psychiatry Investig; 2020 Jul; 17(7):695-701. PubMed ID: 32631031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Korean Version of the Schizophrenia Cognition Rating Scale: Reliability and Validity.
    Kang EC; Kim SJ; Seo YS; Jung SS; Seo BJ; Ryu JW; Shim JC; Moon JJ; Jeon DW; Park KD; Jung DU
    Psychiatry Investig; 2017 Mar; 14(2):141-149. PubMed ID: 28326111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How specific are negative symptoms and cognitive impairment in schizophrenia? An analysis of PANSS and SCoRS.
    Cruz BF; de Resende CB; Abreu MN; Rocha FL; Teixeira AL; Keefe RS; Salgado JV
    Cogn Neuropsychiatry; 2013 May; 18(3):243-51. PubMed ID: 23145794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.
    Green MF; Nuechterlein KH; Kern RS; Baade LE; Fenton WS; Gold JM; Keefe RS; Mesholam-Gately R; Seidman LJ; Stover E; Marder SR
    Am J Psychiatry; 2008 Feb; 165(2):221-8. PubMed ID: 18172017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
    Brown D; Nakagome K; Cordes J; Brenner R; Gründer G; Keefe RSE; Riesenberg R; Walling DP; Daniels K; Wang L; McGinniss J; Sand M
    Schizophr Bull; 2019 Mar; 45(2):350-359. PubMed ID: 29718385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olfactory deficits in individuals at risk for psychosis and patients with schizophrenia: relationship with socio-cognitive functions and symptom severity.
    Takahashi T; Nakamura M; Sasabayashi D; Komori Y; Higuchi Y; Nishikawa Y; Nishiyama S; Itoh H; Masaoka Y; Suzuki M
    Eur Arch Psychiatry Clin Neurosci; 2018 Oct; 268(7):689-698. PubMed ID: 29071372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The reliability and validity of the MATRICS functional assessment battery.
    Velligan DI; Fredrick M; Mintz J; Li X; Rubin M; Dube S; Deshpande SN; Trivedi JK; Gautam S; Avasthi A; Kern RS; Marder SR
    Schizophr Bull; 2014 Sep; 40(5):1047-52. PubMed ID: 24214931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.